Host Ruth Mukwana speaks with Dr Meg Doherty, Director of Science for Health, WHO, Prof. Hugo Kavunga-Membo, Principal Investigator, INRB, and Aurélia Nguyen, Deputy Chief Executive Officer, CEPI on the launch of the Tumaini Vaccine Trial. The trial marks a historic milestone in the global fight against Ebola and other emerging infectious diseases. Named Tumaini, meaning “hope” in Swahili, the pivotal Phase 2/3 study will assess the safety, immunogenicity and efficacy of vaccine candidates against Bundibugyo virus, a rare Ebola virus species for which there is currently no approved vaccine. The first participant was vaccinated in Bunia, Ituri Province, on 23 October 2026. The trial is co-led and co-sponsored by the Institut National de Recherche Biomédicale (INRB) and the University of Antwerp, with national leadership from the DRC Ministry of Health. CEPI provides funding, scientific expertise and operational support, while WHO, Africa CDC, Epicentre, Médecins Sans Frontières and the Institute of Tropical Medicine Antwerp support the effort.